Dashboard
1
Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 8.63
2
Healthy long term growth as Net Sales has grown by an annual rate of 280.07% and Operating profit at 191.98%
3
Flat results in Mar 25
4
With ROE of 14.9, it has a attractive valuation with a 3.5 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
PKR 20,303 Million (Small Cap)
24.00
NA
0.00%
0.16
8.08%
1.83
Revenue and Profits:
Net Sales:
3,341 Million
(Quarterly Results - Mar 2025)
Net Profit:
220 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.71%
0%
-7.71%
6 Months
25.24%
0%
25.24%
1 Year
192.37%
0%
192.37%
2 Years
279.79%
0%
279.79%
3 Years
159.56%
0%
159.56%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Citi Pharma Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
59.49%
EBIT Growth (5y)
78.07%
EBIT to Interest (avg)
8.63
Debt to EBITDA (avg)
0.27
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
1.62
Tax Ratio
30.09%
Dividend Payout Ratio
89.64%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
23.56%
ROE (avg)
13.90%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
1.95
EV to EBIT
14.04
EV to EBITDA
12.71
EV to Capital Employed
1.85
EV to Sales
1.71
PEG Ratio
3.39
Dividend Yield
NA
ROCE (Latest)
13.19%
ROE (Latest)
8.21%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
3,341.10
3,534.40
-5.47%
Operating Profit (PBDIT) excl Other Income
452.20
459.30
-1.55%
Interest
99.10
67.90
45.95%
Exceptional Items
0.00
0.00
Consolidate Net Profit
220.40
257.00
-14.24%
Operating Profit Margin (Excl OI)
118.40%
123.90%
-0.55%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is -5.47% vs 9.61% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is -14.24% vs 27.54% in Dec 2024
Annual Results Snapshot (Consolidated) - Jun'24
Jun'24
Jun'23
Change(%)
Net Sales
12,409.20
12,397.00
0.10%
Operating Profit (PBDIT) excl Other Income
1,233.30
1,182.50
4.30%
Interest
299.90
140.50
113.45%
Exceptional Items
40.40
-19.30
309.33%
Consolidate Net Profit
833.50
658.00
26.67%
Operating Profit Margin (Excl OI)
88.20%
88.10%
0.01%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2024 is 0.10% vs 26.76% in Jun 2023
Consolidated Net Profit
YoY Growth in year ended Jun 2024 is 26.67% vs 0.66% in Jun 2023
About Citi Pharma Ltd. 
Citi Pharma Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






